Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration (dry-AMD) based on the ongoing Phase I/IIa clinical trial will be presented at the Association for Research in Vision and Opthalmology (ARVO) meeting taking place from May 7-11,